vs
Side-by-side financial comparison of ADMA BIOLOGICS, INC. (ADMA) and Palomar Holdings, Inc. (PLMR). Click either name above to swap in a different company.
Palomar Holdings, Inc. is the larger business by last-quarter revenue ($253.4M vs $139.2M, roughly 1.8× ADMA BIOLOGICS, INC.). On growth, Palomar Holdings, Inc. posted the faster year-over-year revenue change (62.7% vs 18.4%). Palomar Holdings, Inc. produced more free cash flow last quarter ($409.0M vs $34.6M). Over the past eight quarters, Palomar Holdings, Inc.'s revenue compounded faster (46.2% CAGR vs 30.4%).
ADMA Biologics Inc. is a biopharmaceutical enterprise focused on the research, development, manufacturing and commercialization of specialty plasma-derived immunoglobulin therapies. It primarily operates in the United States, catering to patients with primary immunodeficiency and other immune-related disorders, healthcare providers and medical institutions across its core immune health therapeutic segment.
Palomar Holdings, Inc. is a specialty insurance holding company that primarily provides property insurance products for catastrophe-exposed residential and commercial assets. It mainly operates across the United States, focusing on core segments including earthquake, flood, and windstorm coverage to meet high-risk property protection demands of customers.
ADMA vs PLMR — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $139.2M | $253.4M |
| Net Profit | $49.4M | — |
| Gross Margin | 63.8% | — |
| Operating Margin | 45.1% | 28.7% |
| Net Margin | 35.5% | — |
| Revenue YoY | 18.4% | 62.7% |
| Net Profit YoY | -55.9% | — |
| EPS (diluted) | $0.20 | $2.05 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $139.2M | $253.4M | ||
| Q3 25 | $134.2M | $244.7M | ||
| Q2 25 | $122.0M | $203.3M | ||
| Q1 25 | $114.8M | $174.6M | ||
| Q4 24 | $117.5M | $155.8M | ||
| Q3 24 | $119.8M | $148.5M | ||
| Q2 24 | $107.2M | $131.1M | ||
| Q1 24 | $81.9M | $118.5M |
| Q4 25 | $49.4M | — | ||
| Q3 25 | $36.4M | $51.5M | ||
| Q2 25 | $34.2M | $46.5M | ||
| Q1 25 | $26.9M | $42.9M | ||
| Q4 24 | $111.9M | — | ||
| Q3 24 | $35.9M | $30.5M | ||
| Q2 24 | $32.1M | $25.7M | ||
| Q1 24 | $17.8M | $26.4M |
| Q4 25 | 63.8% | — | ||
| Q3 25 | 56.3% | — | ||
| Q2 25 | 55.1% | — | ||
| Q1 25 | 53.2% | — | ||
| Q4 24 | 53.9% | — | ||
| Q3 24 | 49.8% | — | ||
| Q2 24 | 53.6% | — | ||
| Q1 24 | 47.8% | — |
| Q4 25 | 45.1% | 28.7% | ||
| Q3 25 | 38.0% | 27.4% | ||
| Q2 25 | 35.1% | 29.5% | ||
| Q1 25 | 30.4% | 30.8% | ||
| Q4 24 | 32.6% | 28.9% | ||
| Q3 24 | 33.1% | 25.9% | ||
| Q2 24 | 36.6% | 25.5% | ||
| Q1 24 | 26.7% | 29.0% |
| Q4 25 | 35.5% | — | ||
| Q3 25 | 27.1% | 21.0% | ||
| Q2 25 | 28.1% | 22.9% | ||
| Q1 25 | 23.4% | 24.6% | ||
| Q4 24 | 95.2% | — | ||
| Q3 24 | 30.0% | 20.5% | ||
| Q2 24 | 29.9% | 19.6% | ||
| Q1 24 | 21.7% | 22.3% |
| Q4 25 | $0.20 | $2.05 | ||
| Q3 25 | $0.15 | $1.87 | ||
| Q2 25 | $0.14 | $1.68 | ||
| Q1 25 | $0.11 | $1.57 | ||
| Q4 24 | $0.45 | $1.29 | ||
| Q3 24 | $0.15 | $1.15 | ||
| Q2 24 | $0.13 | $1.00 | ||
| Q1 24 | $0.08 | $1.04 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $87.6M | $106.9M |
| Total DebtLower is stronger | $72.1M | — |
| Stockholders' EquityBook value | $477.3M | $942.7M |
| Total Assets | $624.2M | $3.1B |
| Debt / EquityLower = less leverage | 0.15× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $87.6M | $106.9M | ||
| Q3 25 | $61.4M | $111.7M | ||
| Q2 25 | $90.3M | $81.3M | ||
| Q1 25 | $71.6M | $119.3M | ||
| Q4 24 | $103.1M | $80.4M | ||
| Q3 24 | $86.7M | $86.5M | ||
| Q2 24 | $88.2M | $47.8M | ||
| Q1 24 | $45.3M | $61.4M |
| Q4 25 | $72.1M | — | ||
| Q3 25 | $72.4M | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $72.3M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $477.3M | $942.7M | ||
| Q3 25 | $431.2M | $878.1M | ||
| Q2 25 | $398.3M | $847.2M | ||
| Q1 25 | $373.4M | $790.4M | ||
| Q4 24 | $349.0M | $729.0M | ||
| Q3 24 | $231.9M | $703.3M | ||
| Q2 24 | $188.3M | $532.6M | ||
| Q1 24 | $153.7M | $501.7M |
| Q4 25 | $624.2M | $3.1B | ||
| Q3 25 | $568.7M | $2.9B | ||
| Q2 25 | $558.4M | $2.8B | ||
| Q1 25 | $510.6M | $2.4B | ||
| Q4 24 | $488.7M | $2.3B | ||
| Q3 24 | $390.6M | $2.3B | ||
| Q2 24 | $376.4M | $2.0B | ||
| Q1 24 | $350.9M | $1.9B |
| Q4 25 | 0.15× | — | ||
| Q3 25 | 0.17× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.21× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $35.6M | $409.1M |
| Free Cash FlowOCF − Capex | $34.6M | $409.0M |
| FCF MarginFCF / Revenue | 24.8% | 161.4% |
| Capex IntensityCapex / Revenue | 0.8% | 0.1% |
| Cash ConversionOCF / Net Profit | 0.72× | — |
| TTM Free Cash FlowTrailing 4 quarters | $27.8M | $700.6M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $35.6M | $409.1M | ||
| Q3 25 | $13.3M | $83.6M | ||
| Q2 25 | $21.1M | $120.9M | ||
| Q1 25 | $-19.7M | $87.2M | ||
| Q4 24 | $50.2M | $261.2M | ||
| Q3 24 | $25.0M | $100.3M | ||
| Q2 24 | $45.6M | $55.1M | ||
| Q1 24 | $-2.2M | $33.1M |
| Q4 25 | $34.6M | $409.0M | ||
| Q3 25 | $-1.1M | $83.6M | ||
| Q2 25 | $18.7M | $120.8M | ||
| Q1 25 | $-24.4M | $87.1M | ||
| Q4 24 | $47.5M | $260.9M | ||
| Q3 24 | $24.0M | $100.1M | ||
| Q2 24 | $43.6M | — | ||
| Q1 24 | $-4.6M | — |
| Q4 25 | 24.8% | 161.4% | ||
| Q3 25 | -0.8% | 34.2% | ||
| Q2 25 | 15.3% | 59.4% | ||
| Q1 25 | -21.2% | 49.9% | ||
| Q4 24 | 40.4% | 167.5% | ||
| Q3 24 | 20.0% | 67.4% | ||
| Q2 24 | 40.7% | — | ||
| Q1 24 | -5.6% | — |
| Q4 25 | 0.8% | 0.1% | ||
| Q3 25 | 10.7% | 0.0% | ||
| Q2 25 | 2.0% | 0.0% | ||
| Q1 25 | 4.1% | 0.0% | ||
| Q4 24 | 2.3% | 0.2% | ||
| Q3 24 | 0.9% | 0.1% | ||
| Q2 24 | 1.9% | 0.0% | ||
| Q1 24 | 2.9% | 0.0% |
| Q4 25 | 0.72× | — | ||
| Q3 25 | 0.36× | 1.63× | ||
| Q2 25 | 0.62× | 2.60× | ||
| Q1 25 | -0.73× | 2.03× | ||
| Q4 24 | 0.45× | — | ||
| Q3 24 | 0.70× | 3.29× | ||
| Q2 24 | 1.42× | 2.14× | ||
| Q1 24 | -0.12× | 1.26× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ADMA
| ADMA Bio Manufacturing Segment | $123.1M | 88% |
| Other | $16.0M | 12% |
PLMR
Segment breakdown not available.
